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Abstract: The first synthesis of the marine fungus derived 
natural product alternaramide is described using solution phase 
coupling protocols and via a macrolactonization and 
macrolactamization route. The structure of alternaramide was 
confirmed and was supported by single crystal X-ray analysis 
which exhibited three similar molecules in the asymmetric unit, 
each with trans-annular hydrogen bonds. 
Key words: Natural product, depsipeptide, peptide coupling, 
macrolactonization, macrolactamization. 
Alternaramide 1 (Figure 1) is a cyclic depsipeptide
1 
isolated from the marine-derived fungus Alternaria sp. SF-
5016 by Oh and co-workers in 2009.
2
  
 
Figure 1. The reported
2
 structure of alternaramide 1 and related 
marine-derived depsipeptide natural products. 
The structure of 1 is related to several depsipeptides isolated 
from marine-derived fungi, such as the exumolides 2 from 
Scytalidium sp.,
3
 sansalvamide A 3 from Fusarium sp.,
4
 and 
zygosporamide 4 from Zygosporium masonii.,
5
 and was 
confirmed using a mixture of 
1
H / 
13
C NMR, degradation 
and Mosher’s ester derivitization studies. This showed that 
the depsipeptide contained 4 amino acid residues (two L-
Pro and two D-Phe) and one hydroxy acid residue (L-Hiv) 
linked by 4 amide and 1 ester linkage. While all these 
peptides possess hydrophobic amino acid residues, the 
presence of the D-Phe residue in 1 is unusual since the only 
other depsipeptide in this group to have D-amino acid 
residues is zygosporamide 4 (Figure 1). Additionally, the 
importance of a D-amino acid in analogues of sansalvamide 
A, in relation to anticancer activity, has been determined by 
McGuire and McAlpine via SAR studies.
6-10
 Total syntheses 
of 3
11
 and 4
12
 have been described previously, however the 
total synthesis of 1 has yet to be reported. Therefore, in this 
letter, we would like to report a short, efficient, solution 
phase total synthesis of 1, confirmation of its reported 
structure and a single crystal X-ray analysis. 
The retrosynthesis of 1 is shown in Scheme 1. 
Alternaramide 1 can be obtained via either a 
macrolactonization or a macrolactamization event on the 
precursor linear peptides 5 and 6, respectively. While there 
are examples of the use macrolactonization in the synthesis 
of depsipeptides,
13-16
 such a cyclisation performed on 5 may 
be problematic. However, due to the short synthetic 
sequence to give the precursor 5 we thought this would be a 
viable route to explore, alongside the macrolactamization 
approach. The synthesis of both precursor linear peptides 5 
and 6 would be from the key tetrapeptide 7 using standard 
peptide coupling protocols. The tetrapeptide 7 would be 
obtained from L-Pro, D-Phe, and L-Hiv, which can be 
obtained from L-Val via hydrolytic diazotization. 
 
Scheme 1. Retrosynthetic analysis of alternaramide 1. 
Coupling of proline methyl ester 8 with HO(D)PheHNBoc 
9 was initially performed using two coupling methods, 
either EDC or formation of the mixed anhydride which gave 
the diamino acid 12 in a good yield of 87% and 86%, 
respectively (Scheme 2). PyBOP
®
 was also employed but 
yields using this coupling reagent were moderate to poor. 
The TBS protected α-hydroxy acid 13 was obtained in 3-
steps in 65% yield via the hydrolytic diazotization of L-Val 
10 followed by TBS protection.
17
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Scheme 2. (a) EDC, MeO(L)ProNH2.HCl, CH2Cl2, 
i
Pr2NEt, [87%]; 
(b) EtO2CCl, NMM, CH2Cl2, 0°C then, MeO(L)ProNH2.HCl, 
[86%]; (c) NaNO2, H2SO4 (d) (i) TBSCl, DMF, imidazole (ii) 
K2CO3, MeOH, H2O [65% over 2-steps]. 
The key tetrapeptide 7 was obtained in 2-steps from 12, by 
Boc deprotection of 12 with 4M HCl in 1,4-dioxine to give 
14, and the hydrolysis of 12 to the free acid using LiOH to 
give 15, both of which were used without further 
purification. The salt 14 and free acid 15 were then coupled 
under EDC conditions to give the key tetra-aminoacid 7 in 
52% yield over the 2-steps (Scheme 3).  
 
Scheme 3. (a) 4M HCl in 1,4-dioxane; (b) LiOH, THF, MeOH, 
H2O; (c) EDC, CH2Cl2, 
i
Pr2NEt2 [52% over 2-steps]; (d) 4M HCl 
in 1,4-dioxane; (e) PyBOP
®
, CH2Cl2, 
i
Pr2NEt [71% over 2-steps]; 
(f) TBAF, THF; (g) LiOH, THF, MeOH, H2O; (h) PyBOP
®
, 
CH2Cl2, 
i
Pr2NEt [5% over 3-steps]. 
Subsequently, 7 was Boc deprotected and the resultant salt 
16 then coupled with the 13 using PyBOP
®
 giving 17 in a 
good yield of 71% over 2-steps. The free alcohol and acid 
on 17 were then sequentially revealed by deprotection using 
TBAF and followed by treatment with excess aqueous 
LiOH. Attempted final ring closure of 5 was then trialed 
with a number of coupling reagents including PyBOP
®
, 
DCC, EDC and 1,3,5-trichlorobenzoyl chloride.
18
 The only 
successful conditions were using excess PyBOP
®
 and 
diisopropylethylamine which provided alternaramide 1 in a 
poor isolated yield of only 5% over the 3-steps, presumably 
due to the low nucleophilicity of the hydroxyl group. 
Consequently, route B (Scheme 1) with the final ring 
closure via a macrolactamization was pursued.  
The requisite substrate for the macrolactamization was 
synthesized in 4-steps from the key tetrapeptide 7 (Scheme 
4). A protecting group switch on the L-Hiv fragment was 
achieved in 2-steps to give the benzyl ester protected L-Hiv 
fragment 19 in 52% yield. This was then successfully 
coupled to the saponified tetrapeptide 20 in 73% yield over 
the 2-steps. Finally, the free acid and amine on 20 were 
revealed by sequential hydrogenolysis followed by acid 
mediated Boc deprotection. The macrolactamization of 6 
was then achieved using excess PyBOP
®
 with diisopropyl 
amine and catalytic DMAP, giving alternaramide 1 in 48% 
yield over the 3-steps.
19
 
 
Scheme 4. (a) BnC(O)Cl, CH2Cl2, Et3N, DMAP; (b) TBAF, THF 
[52% over 2-steps]; (c) LiOH, MeOH, THF, H2O; (d) PyBOP
®
, 
CH2Cl2, 
i
Pr2NEt [73% over 2-steps]; (e) Pd-C (10%), H2, MeOH; 
(f) 4M HCl in 1,4-dioxane; (g) PyBOP
®
,  CH2Cl2, 
i
Pr2Net, DMAP 
(cat.) [48% over 3-steps]. 
The spectroscopic data for our synthetic alternaramide 
sample agreed well with that reported by Oh and co-
workers and copies of the relevant 
1
H and 
13
C NMR spectra 
are contained within the supplementary information.
20,21
 
Crystals suitable for single crystal X-ray analysis were 
obtained and Figure 2 shows the molecular depiction of one 
of three similar molecules of (-)-1 in the asymmetric unit.
22
 
Despite the use of Mo-Kα radiation for this light atom 
structure, determination of the absolute structure 
parameter
23
 via Parson’s Q-value method
24
 led to a value 
that supported the proposed absolute structure for the 
molecule. The molecular conformation is stabilised by 
trans-annular hydrogen bonds. 
 
Figure 2. Crystal structure representation of alternaramide (-)-1.
22
 
In conclusion, we have reported the first total synthesis of 
alternaramide (-)-1 using standard solution phase peptide 
coupling protocols. Two synthetic pathways have been 
investigated using a macrolactonization and a 
macrolactamization approach giving alternaramide in a best 
overall yield of 11% in 8-steps. Finally, the structure of 
synthetic alternaramide (-)-1 was confirmed by single 
crystal X-ray analysis.  
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Supporting Information for this article includes the 1H 
and 
13
C NMR spectra of synthetic alternaramide (-)-1 and 
crystallographic data for (-)-1. 
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(CH2); HRMS MNa
+, C20H28N2O5, found 399.1885, 
requires 399.1896. 
MeO(L)Pro(D)Phe(L)Pro(D)PheNHBoc (-)-7. White foam 
(0.97 g, 52% over 2-steps); Rf (3:1 ethyl acetate:petroleum 
ether) 0.38; [α]D
21 -8.1 (c 1, CHCl3); νmax (solution, 
CHCl3) 3584, 3295, 2980, 1742, 1642, 1497, 1449, 1171 
cm-1; δH (400 MHz; CDCl3) 7.25 – 7.17 (m, 10H), 5.51 (d, 
J = 7.6 Hz, 1H), 4.86 (dt, J = 6.4, 8.4 Hz, 1H), 4.57 – 4.54 
(m, 1H), 4.36 (dd, J = 2.4, 8.0 Hz, 1H), 4.27 (dd, J = 4.0, 
8.4 Hz, 1H), 3.68 (s, 3H), 3.53 – 3.49 (m, 2H), 3.02 – 2.93 
(m, 4H), 2.77 – 2.75 (m, 1H), 2.63 – 2.60 (m, 1H), 2.46 (s, 
1H), 2.03 – 1.98 (m, 1H), 1.93 – 1.78 (m, 4H), 1.61 – 1.50 
(m, 3H), 1.41 (s, 9H); δC (100 MHz; CDCl3) 172.31 (C), 
171.08 (C), 170.43 (C), 169.53 (C), 155.21 (C), 136.62 
(C), 129.54 (CH), 129.50 (CH), 129.33 (C), 128.46 (CH), 
128.34 (CH), 126.94 (CH), 126.84 (CH), 79.75 (C), 60.16 
(CH), 58.80 (CH), 53.92 (CH3), 52.42 (CH), 52.22 (CH), 
46.84 (CH2), 46.69 (CH2), 39.63 (CH2), 39.00 (CH2), 
28.91 (CH2), 28.37 (CH3) (NB masked CH2), 24.51 (CH2), 
24.18 (CH2); HRMS MNa
+, C34H44N4O7, found 643.3098, 
requires 643.3108. 
MeO(L)Pro(D)Phe(L)Pro(D)Phe(L)HivOTBS (-)-17. 
Colourless foam (0.52 g, 71% over 2-steps); Rf (ethyl 
acetate) 0.78; [α]D
16 -12.4 (c 1, CHCl3); νmax (solution, 
CHCl3) 3416, 3290, 2957, 1743, 1658, 1515, 1451, 1254, 
1052 cm-1; δH (400 MHz; CDCl3) 7.27 – 7.13 (m, 10H), 
7.07 (d, J = 7.6 Hz, 2H), 4.87 – 4.82 (m , 1H), 4.77 – 4.73 
(m, 1H), 4.41 (dd, J = 2.4, 8.4 Hz, 1H), 4.23 (dd, J = 4.0, 
7.6 Hz, 1H), 3.96 (s, 3H, 3.01 – 2.88 (m, 4H), 2.68 – 2.64 
(m, 1H), 2.57 – 2.52 (m, 1H), 2.48 – 2.44 (m, 1H), 2.09 – 
2.02 (m, 1H), 1.99 – 1.95 (m, 1H), 1.88 – 1.75 (m, 5H), 
1.66 – 1.60 (m, 1H), 1.51 – 1.46 (m, 2H), 0.92 – 0.90 (m, 
15H), 0.40 (s, 3H), -0.05 (s, 3H); δC (100 MHz; CDCl3) 
173.83 (C), 172.28 (C), 170.63(C), 170.51(C), 169.91(C), 
136.72 (C), 135.69 (C), 129.44 (CH), 129.31 (CH), 128.68 
(CH), 128.34 (CH), 127.33 (CH), 126.82 (CH), 77.38 
(CH), 60.53 (CH), 58.72 (CH), 52.45 (CH), 52.28 (CH), 
52.09 (CH3), 46.77 (CH2), 46.68 (CH2), 38.79 (CH2), 
38.76 (CH2), 32.62 (C), 29.39 (CH2), 28.91 (CH2), 25.76 
(CH2), 24.40 (CH2), 23.69 (CH2), 19.60 (CH3), 18.07 
(CH3), 16.00 (C), -5.00 (CH3), -5.09 (CH3); HRMS MNa
+, 
C40H58N4O7Si1, found 757.3955, requires 757.3972. 
BnO(L)Hiv(L)Pro(D)Phe(L)Pro(D)PheNHBoc   (-)-21. 
Colourless foam (0.19 g, 73% over 2-steps); Rf (3:1 ethyl 
acetate:petroleum ether) 0.65; [α]D
18 -6.4 (c 1, CHCl3); 
νmax (film) 3584, 3413, 2965, 2248, 1747, 1685, 1645, 
1454, 1172 cm-1; δH (400 MHz; CDCl3) 7.27 – 7.14 (m, 
15H), 7.07 – 7.05 (m, 1H), 5.41 (d, J = 7.6 Hz, 1H), 5.08 
(dd, J = 12.0, 12.4 Hz, 2H), 4.94 (t, J = 4.4 Hz, 1H), 4.87 
(q, J = 7.2 Hz, 1H), 4.59 – 4.56 (m, 1H), 4.40 (dd, J = 3.6, 
8.4 Hz, 1H), 4.32 (dd, J = 2.8, 8.4 Hz, 1H), 3.56 – 3.53 
(m, 2H), 2.99 – 2.94 (m, 4H), 2.74 – 2.68 (m, 1H), 2.61 – 
2.49 (m, 2H), 2.30 – 2.29 (m, 1H), 2.27 – 2.24 (m, 1H), 
1.96 – 1.50 (m, 6H), 1.39 (s, 9H), 1.03 (d, J = 6.8 Hz, 3H), 
0.97 (d, J = 6.8 Hz, 3H); δC (100 MHz; CDCl3) (one 
carbon masked) 172.10 (C), 171.12 (C), 170.60 (C), 
169.68 (C), 169.46 (C), 168.93 (C), 136.59 (C), 135.21 
(C), 135.02 (C), 129.53 (CH), 129.49 (CH), 128.63 (CH), 
128.57 (CH), 128.45 (CH), 128.39 (CH), 128.32 (CH), 
126.93 (CH), 126.84 (CH), 79.72 (CH), 77.58 (CH), 67.18 
(CH2), 66.93 (CH2), 60.36 (CH), 58.42 (CH), 53.86 (CH), 
52.44 (CH), 46.88 (CH2), 46.73 (CH2), 38.97 (CH2), 31.92 
(CH2), 30.18 (CH3), 29.69 (CH2), 28.38 (CH2), 24.23 
(CH2), 18.62 (CH3), 17.15 (CH3); HRMS MNa
+, 
C45H56N4O9, 819.3899, requires 819.3945. 
(20) Alternaramide (-)-1. Colourless crystalline solid (77 mg, 
48% over 3-steps) m.p. 217 – 218.5 °C (recrystallised 
from CH2Cl2 / petroleum ether); Rf (3:1 ethyl 
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acetate:petroleum ether) 0.48; [α]D
19 -2.8 (c 0.5, MeOH); 
νmax (film) 3584, 3480, 3300, 3029, 2961, 2929, 2875, 
2248, 1744, 1683, 1643, 1634, 1529, 1452, 1275, 1094 
cm-1; δH (400 MHz; CDCl3) 8.12 (d, J = 9.6 Hz, 1H), 7.32 
– 7.17 (m, 11H), 5.34 (d, J = 2.4 Hz, 1H), 5.02 – 4.91 (m, 
2H), 4.85 (d, J = 7.2 Hz, 1H), 4.30 (dd, J = 5.2, 8.8 Hz, 
1H), 3.46 – 3.41 (m, 1H), 3.35 (dd, J = 9.2, 13.2 Hz, 1H), 
3.26 (m, 2H), 3.03 – 2.99 (m, 2H), 2.90 (dd, J = 5.2, 13.2 
Hz, 1H), 2.54 – 2.49 (m, 2H), 2.44 – 2.42 (m, 1H), 1.99 - 
1.93 (m, 2H), 1.93 – 1.84 (m, 2H), 1.78 – 1.72 (m, 1H), 
1.69 – 1.63 (m, 1H), 1.46 (sept, J = 6.8 Hz, 1H), 0.82 (d, J 
= 6.8 Hz, 3H), 0.71 (d, J = 6.8 Hz, 3H); δC (100 MHz; 
CDCl3) 171.16 (C), 169.66 (C), 169.19 (C), 168.86 (C), 
167.26 (C), 136.49 (C), 135.00 (C), 128.66 (CH), 128.30 
(CH), 127.58 (CH), 127.36 (CH), 126.29 (C), 125.48 (C), 
75.95 (CH), 58.92 (CH), 57.28 (CH), 51.85 (CH), 51.13 
(CH), 45.89 (CH2), 44.94 (CH2), 39.43 (CH2), 35.95 
(CH2), 28.65 (CH), 28.50 (CH2), 23.75 (CH2), 23.48 
(CH2), 18.09 (CH3), 14.83 (CH3) ; HRMS MNa
+, 
C33H40N4O6, found 611.2833, requires 611.2846.  
(21) See supporting information for copies of the 1H, 13C NMR 
spectra for synthetically prepared alternaramide (-)-1.  
(22) Crystal data for (-)-1: C33H40N4O6, M = 588.69, 
orthorhombic, P212121; a = 12.0808(4) b = 22.0624(7), c = 
34.9650(11) Å, V = 9319.3(5) Å3; Dcalc = 1.259 g/cm
3; 
μ –Kα) = 0.087 mm1; λ = 0.71073 Å, T = 150(2) K; 
104556 total reflections, 26198 unique data (Rint = 
0.0456); Solved by direct methods and refined on F2 
values to give R1= 0.0473 [F2>2σ(F2)] (19948 observed 
reflections), wR2 = 0.1107 (all data). Absolute structure 
parameter = –0.09(22)23,24. CCDC: 801185 contains the 
supplementary crystallographic data for compound (-)-1. 
These data can be obtained free of charge via 
http://www.ccdc.cam.ac.uk/data_request/cif or from the 
Cambridge Crystallographic Data Centre, 12 Union Road, 
Cambridge, CB2 1EZ, UK; fax: (+44) 1223 336 033 or e-
mail: deposit@ccdc.cam.ac.uk.. 
(23) Flack, H. D., Acta Crystallogr., 1983, A39, 876. 
(24) Parsons, S., University of Edinburgh. 
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